BAXのチャート
BAXの企業情報
| symbol | BAx |
|---|---|
| 会社名 | Baxter International Inc （BAX バクスタ― インタ―ナショナル） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 バクスター・インターナショナル（Baxter International Inc.）は子会社を通じて腎臓及び病院用製品を提供する。同社は2つの事業区分を運営する。病院製品事業は、滅菌静脈内（IV）溶液および投与セット、予混合薬剤および薬剤再構成システム、注射剤、IV栄養製品、非経口栄養療法、輸液ポンプ、吸入麻酔薬およびバイオ手術用製品のための充填済みバイアルおよびシリンジを製造する。レナール事業は、末期腎疾患、または腎臓疾患および急性腎障害の患者のニーズに応じて、腹膜透析（PD）、血液透析（HD）、継続的腎代替療法（CRRT）および追加の透析サービス等のポートフォリオを提供する。同社の製品は、病院、腎臓透析センター、老人ホーム、リハビリテーションセンター、医院、および医師の監督の下で自宅にいる患者によって使用されている。 バクスタ―・インタ―ナショナルは米国の医療機器・医薬品メ―カ―。事業は2部門で構成。バイオサイエンス部門は血友病治療用血漿タンパク製剤などの生物薬剤製品のほか、免疫不全症や止血用の生物学的組織接着剤などの製造を行う。医療製品部門は静脈内投与用の注射器などを製造、腹膜透析用減菌透析液、院内用血液透析装置も扱う。本社はイリノイ州。 Every day, millions of patients and caregivers rely on Baxter's leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, it has been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company's rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. |
| 本社所在地 | One Baxter Parkway Deerfield IL 60015 USA |
| 代表者氏名 | Jose E. Almeida |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer |
| 電話番号 | +1 847-948-2000 |
| 設立年月日 | 11597 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 50000人 |
| url | www.baxter.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | EBITDA（百万ドル） 2545.00000 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | 時価総額（百万ドル） 41558.95000 |
| 売上高 | 売上高（百万ドル） 11127.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 43202.95000 |
| 当期純利益 | 当期純利益（百万ドル） 1423.00000 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 31 December 2018 Baxter International Inc revenues increased 5% to $11.13B. Net income before extraordinary items increased 9% to $1.42B. Revenues reflect Americas segment increase of 4% to $5.96B EMEA segment increase of 8% to $2.96B APAC segment increase of 5% to $2.21B United States segment increase of 32% to $5.96B Asia pacific segment increase of 5% to $2.21B. |
BAXのテクニカル分析
BAXのニュース
Express, Inc. (EXPR) Q4 2022 Earnings Call Transcript 2023/03/24 14:43:05 Seeking Alpha
Express, Inc. (NYSE:NYSE:EXPR) Q4 2022 Earnings Conference Call March 24, 2023 9:00 AM ETCompany ParticipantsGreg Johnson - Vice President, Investor RelationsTim Baxter - Chief Executive…
Thermo Fisher among bidders to acquire Baxter''s biopharma unit – Reuters 2023/03/21 17:38:00 Seeking Alpha
Thermo Fisher Scientific (TMO) and South Korea-based Celltrion Inc
Baxter biopharma solutions unit seeing interest from Thermo Fisher, Celltrion - report 2023/03/21 01:43:43 Seeking Alpha
Thermo Fisher (TMO) and South Korea''s Celltrion are competing for Baxter''s (BAX) Biopharma Solutions unit in a sale that could value the business at more than $4 billion.Private…
Exclusive-Thermo Fisher, Celltrion vie for Baxter’s biopharma unit -sources 2023/03/20 21:51:25 FX Empire
By Anirban Sen and David Carnevali (Reuters) -U.S. scientific instruments maker Thermo Fisher Scientific Inc and South Korea’s Celltrion Inc are among those competing to acquire the biopharma solutions business of medical device maker Baxter International Inc, according to people familiar with the matter.
EXCLUSIVE-Thermo Fisher, Celltrion vie for Baxter''s biopharma unit -sources 2023/03/20 21:40:20 Reuters
U.S. scientific instruments maker Thermo Fisher Scientific Inc and South Korea''s Celltrion Inc are among those competing to acquire the biopharma solutions business of medical device maker Baxter International Inc, according to people familiar with the matter.
Baxter International Inc. – Consensus Indicates Potential 16.1% Upside 2023/01/09 12:25:41 DirectorsTalk
Baxter International Inc. found using ticker (BAX) now have 14 analysts in total covering the stock. The consensus rating is ''Buy''. The target price ranges between 73 and 51 and has a mean target at 61.01. With the stocks previous close at 52.57 this would indicate that there is a potential upside of 16.1%. There is a 50 day moving average of 52.76 and the 200 day moving average is 62.43. The market cap for the company is $24,425m. Find out more information at: https://www.baxter.com [stock_market_widget type="chart" template="basic" color="green" assets="BAX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $28,346m based on the market concensus. Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit.
Baxter Plans Divesting Renal Care Business Into Separate Public Company, Shares Fall 2023/01/06 18:33:37 Benzinga
Baxter International Inc (NYSE: BAX ) announced spinning off its Renal Care and Acute Therapies global business unit into an independent, publicly traded company . The new kidney care company will benefit from its existing product portfolio, diverse footprint, commercial operations, and service capabilities that support its therapies delivered in the home, clinics, and intensive care unit. Related:
Baxter International plans to spin off kidney care units 2023/01/06 16:17:24 Financial Post
Baxter International Inc said on Friday it plans to spin off its kidney care units, becoming the latest medical device maker to slim down in the face of supply-chain challenges. Shares of the Deerfield, Illinois-based firm were down about 6% in morning trade. The company plans to spin off its renal care and acute therapies […]
Healthcare Stocks Sell Off Friday 2023/01/06 15:36:03 The Wall Street Journal
Most sectors are rallying on Friday, but healthcare is a glaring exception. Health stocks dominate the list of biggest laggards in the S&P 500. Baxter International shares fell 6% after the hospital products supplier announced it plans to spin off its kidney-care business. Lab equipment maker Ther
Baxter follows botched purchase with major restructuring 2023/01/06 15:35:20 Crain''s Chicago
The Deerfield-based medical products maker plans to spin off its biggest unit into a separate company, among other moves, as it announces a longtime executive''s departure.
Next England head coach odds: Steve Borthwick strong favourite to replace sacked Eddie Jones, Cockerill and Baxter trail 2022/12/06 14:35:29 The Sun
STEVE BORTHWICK is the strong odds-on favourite to replace sacked England head coach Eddie Jones.That''s according to bookmakers Betfair, who''ve instal
BAX stock falls after flagging macro risks to financials (NYSE:BAX) 2022/12/01 20:41:56 Seeking Alpha
Shares of healthcare equipment maker Baxter International (BAX) hit a session low on Thursday after the company warned of a potential recession and explained limits to raise prices at…
Baxter Introduces ExactaMix Pro, Next-Generation Automated Nutrition Compounder, at ASHP Meeting 2022/12/01 14:00:00 Business Wire
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, announces the launch of the ExactaMix Pro Automated Compounder, which is expected to be available to customers in the United States in early 2023. ExactaMix Pro will be on display at Baxter’s booth #937 at the American Society of Health-System Pharmacists (ASHP) 2022 Midyear Clinical Meeting taking place Dec. 4 – Dec. 8, 2022, in Las Vegas. Compounding refers to the process of combining
Kidney Dialysis Equipment Market to Witness Huge Growth by Key Players: Fresenius, Baxter, Nipro, Medtronic, Nikkiso 2022/11/30 12:10:00 OpenPR
The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the Kidney Dialysis Equipment industry. This wide-ranging market research report acts as a backbone for the success of
FDA classifies Baxter’s hospital bed system recall as most serious 2022/11/23 20:48:45 National Post
The U.S. health regulator on Wednesday classified the recall of hospital bed systems by Baxter International Inc, as the most serious type, on concerns it could lead to life-threatening injuries or death. Baxter initiated the recall of its WatchCare Incontinence Management System, which is used to discreetly alert an incontinent patient’s caregiver of involuntary urination […]